BIRMINGHAM, Ala. - In proof-of-concept experiments, University of Alabama at Birmingham researchers have highlighted a potential therapy for a rare but potentially deadly blood-clotting disorder, TTP.

• The American Red Cross and Blood Systems Incorporated (BSI) would be the manufacturers of INTERCEPT plasma for treatment of TTP upon FDA approval and could provide INTERCEPT plasma to other blood ...

Judicious use of caplacizumab (Cablivi) can reduce the risk of severe bleeding and help manage costs associated with the therapy in patients living with thrombotic thrombocytopenic purpura (TTP). The ...

X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment. X. Long Zheng, MD, PhD: What are the unmet needs in acquired TTP [thrombotic thrombocytopenic purpura] ...

In proof-of-concept experiments, University of Alabama at Birmingham researchers have highlighted a potential therapy for a rare but potentially deadly blood-clotting disorder, TTP. The researchers ...

It was a rare, aggressive blood disorder. Large teaching hospitals like the University of Tennessee Medical Center saw two or three cases a year of potentially deadly thrombotic thrombocytopenic ...

In a new study by Yale Cancer Center (YCC) researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care ...

In proof-of-concept experiments, researchers have highlighted a potential therapy for a rare but potentially deadly blood-clotting disorder, TTP. The researchers deliver this therapeutic enzyme via ...